Literature DB >> 14531168

[Malignant hyperthermia].

Fritz Zimprich1, Hans Georg Kress, Josef Zeitlhofer.   

Abstract

Malignant hyperthermia is an autosomal dominant disorder of the skeletal muscle that predisposes affected individuals to a life-threatening hypermetabolic reaction in response to volatile anaesthetics and depolarizing muscle relaxants. The underlying heterogeneous genetic defects are mainly point mutations within the ryanodine receptor gene of the sarcoplasmic reticulum. Following the introduction of efficient diagnostic and therapeutic tools--the in vitro contracture test and intravenous treatment with dantrolene--a dramatic decline in mortality rates has been observed. The association of malignant hyperthermia-like reactions with other neuromuscular disorders requires the collaboration of several clinical disciplines to achieve a timely recognition of this still life-threatening disorder.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14531168     DOI: 10.1007/bf03040449

Source DB:  PubMed          Journal:  Wien Klin Wochenschr        ISSN: 0043-5325            Impact factor:   1.704


  34 in total

1.  Postexercise muscle cramping associated with positive malignant hyperthermia contracture testing.

Authors:  J W Ogletree; J F Antognini; G A Gronert
Journal:  Am J Sports Med       Date:  1996 Jan-Feb       Impact factor: 6.202

2.  Anesthetic-induced malignant hyperpyrexia in children.

Authors:  J O King; M A Denborough
Journal:  J Pediatr       Date:  1973-07       Impact factor: 4.406

Review 3.  Ryanodine receptor mutations in malignant hyperthermia and central core disease.

Authors:  T V McCarthy; K A Quane; P J Lynch
Journal:  Hum Mutat       Date:  2000       Impact factor: 4.878

4.  Histological support for the difference between malignant hyperthermia susceptible (MHS), equivocal (MHE) and negative (MHN) muscle biopsies.

Authors:  P Mezin; J F Payen; J L Bosson; E Brambilla; P Stieglitz
Journal:  Br J Anaesth       Date:  1997-09       Impact factor: 9.166

5.  [4-chloro-m-cresol-induced contractures of skeletal muscle specimen from patients at risk for malignant hyperthermia].

Authors:  F Wappler; J Scholz; V von Richthofen; M Fiege; M Steinfath; J Schulte am Esch
Journal:  Anasthesiol Intensivmed Notfallmed Schmerzther       Date:  1997-09       Impact factor: 0.698

6.  Preparation of the Siemens KION anesthetic machine for patients susceptible to malignant hyperthermia.

Authors:  Guy C Petroz; Jerrold Lerman
Journal:  Anesthesiology       Date:  2002-04       Impact factor: 7.892

Review 7.  Malignant hyperthermia.

Authors:  M Denborough
Journal:  Lancet       Date:  1998-10-03       Impact factor: 79.321

8.  Effects of three different types of management on the elimination kinetics of volatile anaesthetics. Implications for malignant hyperthermia treatment.

Authors:  A Reber; P Schumacher; A Urwyler
Journal:  Anaesthesia       Date:  1993-10       Impact factor: 6.955

9.  In vitro contraction test for malignant hyperthermia in patients with unexplained recurrent rhabdomyolysis.

Authors:  P J Poels; E M Joosten; R C Sengers; A M Stadhouders; J H Veerkamp; A A Benders
Journal:  J Neurol Sci       Date:  1991-09       Impact factor: 3.181

10.  A protocol for the investigation of malignant hyperpyrexia (MH) susceptibility. The European Malignant Hyperpyrexia Group.

Authors: 
Journal:  Br J Anaesth       Date:  1984-11       Impact factor: 9.166

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.